CoChat

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms

Open access
Palomo, Laura, Meggendorfer, Manja, Hutter, Stephan, Twardziok, Sven, Ademà, Vera, Fuhrmann, Irene, Fuster-Tormo, Francisco, Xicoy, Blanca, Zamora, Lurdes, Acha, Pamela, Kerr, Cassandra M., Kern, Wolfgang, Maciejewski, Jaroslaw P., Solé, Francesc, Haferlach, Claudia, Haferlach, Torsten · 2020 · Blood
Cited by 177

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

More than 90% of patients with myelodysplastic/myeloproliferative neoplasms (MDSs/MPNs) harbor somatic mutations in myeloid-related genes, but still, current diagnostic criteria do not include molecular data. We performed genome-wide sequencing techniques to characterize the mutational landscape of a large and clinically well-characterized cohort including 367 adults with MDS/MPN subtypes, including chronic myelomonocytic leukemia (CMML; n = 119), atypical chronic myeloid leukemia (aCML; n = 71), MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; n = 71), and MDS/MPN unclassifiable (MDS/MPN-U; n = 106). A total of 30 genes were recurrently mutated in ≥3% of the cohort. Distribution of recurrently mutated genes and clonal architecture differed among MDS/MPN subtypes. Statistical analysis revealed significant correlations between recurrently mutated genes, as well as genotype-phenotype associations. We identified specific gene combinations that were associated with distinct MDS/MPN subtypes and that were mutually exclusive with most of the other MDSs/MPNs (eg, TET2-SRSF2 in CMML, ASXL1-SETBP1 in aCML, and SF3B1-JAK2 in MDS/MPN-RS-T). Patients with MDS/MPN-U were the most heterogeneous and displayed different molecular profiles that mimicked the ones observed in other MDS/MPN subtypes and that had an impact on the outcome of the patients. Specific gene mutations also had an impact on the outcome of the different MDS/MPN subtypes, which may be relevant for clinical decision-making. Overall, the results of this study help to elucidate the heterogeneity found in these neoplasms, which can be of use in the clinical setting of MDS/MPN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019004229

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 177

Metadata

Authors
Palomo, L., Meggendorfer, M., Hutter, S., Twardziok, S., Ademà, V., Fuhrmann, I., Fuster-Tormo, F., Xicoy, B., Zamora, L., Acha, P., Kerr, C. M., Kern, W., Maciejewski, J. P., Solé, F., Haferlach, C., & Haferlach, T.
Venue
Blood
Published
2020-10-15
Volume
136
Issue
16
Pages
1851-1862
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3037045894
Cited by
177
References
44
FWCI
15.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1182/blood.2019004229
The paper
Palomo, L., Meggendorfer, M., Hutter, S., Twardziok, S., Ademà, V., Fuhrmann, I., Fuster-Tormo, F., Xicoy, B., Zamora, L., Acha, P., Kerr, C. M., Kern, W., Maciejewski, J. P., Solé, F., Haferlach, C., & Haferlach, T. (2020). Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood.2019004229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.